person · Reporting owner

COZADD BRUCE C

Disclosed activity across 3 companies

Tapewire entity: 819
SEC CIK: 0001193210

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CERUS CORPCERS · Entity 5431	Director	June 06, 2017	June 13, 2017
Jazz Pharmaceuticals plcJAZZ · Entity 818	Director	October 01, 2026	October 05, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CERUS CORP

Report date June 06, 2017 · Filed June 13, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	18,921	Reported balance After 2017-06-06 transaction · row 1 1 source row Row 1 · 2017-06-06 · Exercise / conversion · Acquired 10,133 · Balance 18,921 F1: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2017-06-06 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-06-06 · Exercise / conversion · Disposed 10,133 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F3: Not applicable. F2: This restricted stock unit vested on the day prior to the 2017 Annual Meeting of Stockholders.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	15,853	Reported balance After 2017-06-07 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-06-07 · Grant · Acquired 15,853 · Balance 15,853 F1: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F3: Not applicable. F5: The restricted stock unit shall vest on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2018 Annual Meeting of Stockholders.
Option Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $2.61 · Expires 2027-06-06	Direct	38,005	Reported balance After 2017-06-07 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-06-07 · Grant · Acquired 38,005 · Balance 38,005 F3: Not applicable. F4: The option shall vest in twelve (12) equal monthly installments on each monthly anniversary of the transaction date with the final vesting date being the earlier of (a) one year from the date of grant, or (b) the day prior to the 2018 Annual Meeting of Stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock.

F2: This restricted stock unit vested on the day prior to the 2017 Annual Meeting of Stockholders.

F3: Not applicable.

F4: The option shall vest in twelve (12) equal monthly installments on each monthly anniversary of the transaction date with the final vesting date being the earlier of (a) one year from the date of grant, or (b) the day prior to the 2018 Annual Meeting of Stockholders.

F5: The restricted stock unit shall vest on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2018 Annual Meeting of Stockholders.

Jazz Pharmaceuticals plc

Report date October 01, 2026 · Filed October 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	345,875	Reported balance After 2026-10-01 transaction · row 1 1 source row Row 1 · 2026-10-01 · Sale · Disposed 6,000 · Balance 345,875 F1: This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ACELYRIN, Inc.

Report date May 21, 2025 · Filed May 23, 2025

Section 16 reporting ended · disclosed 2025-05-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.04 · Expires 2032-03-07	Direct	Reported balance After 2025-05-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-05-21 · Disposition to issuer · Disposed 183,434 · Balance 0 F2: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F1: 1/48 of the shares subject to the option vested on April 7, 2022, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2033-05-03	Direct	Reported balance After 2025-05-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-05-21 · Disposition to issuer · Disposed 23,243 · Balance 0 F2: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F4: 1/36 of the shares subject to the option vested on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46 · Expires 2034-06-06	Direct	Reported balance After 2025-05-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-05-21 · Disposition to issuer · Disposed 92,158 · Balance 0 F2: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F5: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 1/48 of the shares subject to the option vested on April 7, 2022, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.

F2: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares.

F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent.

F4: 1/36 of the shares subject to the option vested on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.

F5: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 01, 2022 Filed Jun 3, 2022 19:04 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	9,700	$0.00 Strike: $46.83	$0.00	Disclosure SEC source: 0001765581-22-000053 · edgardoc.xml · derivative · entry 8 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,332 Underlying: Ordinary Shares · 9,700 shares Expires 2022-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F8 · derivative.exercise_date: This Non-qualified stock option is part of an option granted on August 9, 2012. The ordinary shares subject to this option vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of August 9, 2016. Read SEC document
June 01, 2022 Filed Jun 3, 2022 19:04 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	489	$149.68	$73,193.52	Disclosure SEC source: 0001765581-22-000053 · edgardoc.xml · nonDerivative · entry 6 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,987 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. Read SEC document
June 01, 2022 Filed Jun 3, 2022 19:04 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	831	$148.82	$123,669.42	Disclosure SEC source: 0001765581-22-000053 · edgardoc.xml · nonDerivative · entry 5 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,476 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F6 · price: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $148.66 to $148.95. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
June 01, 2022 Filed Jun 3, 2022 19:04 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,270	$148.13	$188,125.10	Disclosure SEC source: 0001765581-22-000053 · edgardoc.xml · nonDerivative · entry 4 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,307 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F5 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $147.62 to $148.59. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
June 01, 2022 Filed Jun 3, 2022 19:04 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,360	$146.05	$198,628.00	Disclosure SEC source: 0001765581-22-000053 · edgardoc.xml · nonDerivative · entry 3 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,577 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F4 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $145.84 to $146.513 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
June 01, 2022 Filed Jun 3, 2022 19:04 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	2,412	$145.42	$350,753.04	Disclosure SEC source: 0001765581-22-000053 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,937 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $144.832 to $145.753 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
June 01, 2022 Filed Jun 3, 2022 19:04 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionOrdinary Shares	9,700	$46.83	$454,251.00	Disclosure SEC source: 0001765581-22-000053 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 358,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F2 · balance_after: Includes 147 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2022. Read SEC document
May 02, 2022 Filed May 4, 2022 22:21 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	9,700	$0.00 Strike: $46.83	$0.00	Disclosure SEC source: 0001765581-22-000041 · edgardoc.xml · derivative · entry 7 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,032 Underlying: Ordinary Shares · 9,700 shares Expires 2022-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F7 · derivative.exercise_date: This Non-qualified stock option is part of an option granted on August 9, 2012. The ordinary shares subject to this option vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of August 9, 2016. Read SEC document
May 02, 2022 Filed May 4, 2022 22:21 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,000	$158.67	$158,670.00	Disclosure SEC source: 0001765581-22-000041 · edgardoc.xml · nonDerivative · entry 6 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,502 F6 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
May 02, 2022 Filed May 4, 2022 22:21 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	716	$158.53	$113,507.48	Disclosure SEC source: 0001765581-22-000041 · edgardoc.xml · nonDerivative · entry 5 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,502 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F5 · price: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $157.885 to $158.67. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
May 02, 2022 Filed May 4, 2022 22:21 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	767	$156.97	$120,395.99	Disclosure SEC source: 0001765581-22-000041 · edgardoc.xml · nonDerivative · entry 4 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,218 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F4 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $156.84 to $157.11 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
May 02, 2022 Filed May 4, 2022 22:21 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	3,177	$156.13	$496,025.01	Disclosure SEC source: 0001765581-22-000041 · edgardoc.xml · nonDerivative · entry 3 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,985 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $155.79 to $156.57. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
May 02, 2022 Filed May 4, 2022 22:21 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,600	$155.34	$248,544.00	Disclosure SEC source: 0001765581-22-000041 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,162 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F2 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $154.77 to $155.70. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
May 02, 2022 Filed May 4, 2022 22:21 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionOrdinary Shares	9,700	$46.83	$454,251.00	Disclosure SEC source: 0001765581-22-000041 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,762 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 04, 2022 Filed Apr 6, 2022 21:12 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	9,700	$0.00 Strike: $46.83	$0.00	Disclosure SEC source: 0001765581-22-000036 · edgardoc.xml · derivative · entry 7 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,732 Underlying: Ordinary Shares · 9,700 shares Expires 2022-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: This Non-qualified stock option is part of an option granted on August 9, 2012. The ordinary shares subject to this option vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of August 9, 2016. Read SEC document
April 04, 2022 Filed Apr 6, 2022 21:12 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	3,500	$160.00	$560,000.00	Disclosure SEC source: 0001765581-22-000036 · edgardoc.xml · nonDerivative · entry 6 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,062 F5 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
April 04, 2022 Filed Apr 6, 2022 21:12 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,000	$158.64	$158,640.00	Disclosure SEC source: 0001765581-22-000036 · edgardoc.xml · nonDerivative · entry 5 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,562 F5 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
April 04, 2022 Filed Apr 6, 2022 21:12 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,294	$158.37	$204,933.63	Disclosure SEC source: 0001765581-22-000036 · edgardoc.xml · nonDerivative · entry 4 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,562 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F4 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $157.95 to $158.65 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
April 04, 2022 Filed Apr 6, 2022 21:12 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	3,228	$157.49	$508,362.23	Disclosure SEC source: 0001765581-22-000036 · edgardoc.xml · nonDerivative · entry 3 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,856 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $156.905 to $157.88. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
April 04, 2022 Filed Apr 6, 2022 21:12 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,750	$156.33	$273,569.28	Disclosure SEC source: 0001765581-22-000036 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,084 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F2 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $155.88 to $156.8775. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
April 04, 2022 Filed Apr 6, 2022 21:12 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionOrdinary Shares	9,700	$46.83	$454,251.00	Disclosure SEC source: 0001765581-22-000036 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 17, 2022 Filed Mar 21, 2022 18:01 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionIncentive Stock Option (right to buy) · Derivative	1,288	$0.00 Strike: $59.13	$0.00	Disclosure SEC source: 0001765581-22-000034 · edgardoc.xml · derivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,288 shares Expires 2023-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This incentive stock option is part of an option granted on March 5, 2013. The ordinary shares subject to this option vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of March 5, 2017. Read SEC document
March 17, 2022 Filed Mar 21, 2022 18:01 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionOrdinary Shares	1,288	$59.13	$76,159.44	Disclosure SEC source: 0001765581-22-000034 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 05, 2022 Filed Mar 9, 2022 22:52 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Tax withholdingOrdinary Shares	21,929	$153.96	$3,376,188.84	Disclosure SEC source: 0001765581-22-000015 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,846 F2 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document
March 03, 2022 Filed Mar 9, 2022 22:52 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantOrdinary Shares	44,788	$0.00	$0.00	Disclosure SEC source: 0001765581-22-000015 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,775 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2022, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document
March 02, 2022 Filed Mar 3, 2022 21:37 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	6,000	$150.00	$900,000.00	Disclosure SEC source: 0001765581-22-000011 · edgardoc.xml · nonDerivative · entry 5 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,987 F5 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
March 01, 2022 Filed Mar 3, 2022 21:37 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	9,700	$0.00 Strike: $46.83	$0.00	Disclosure SEC source: 0001765581-22-000011 · edgardoc.xml · derivative · entry 6 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,432 Underlying: Ordinary Shares · 9,700 shares Expires 2022-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: This Non-qualified stock option is part of an option granted on August 9, 2012. The ordinary shares subject to this option vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of August 9, 2016. Read SEC document
March 01, 2022 Filed Mar 3, 2022 21:37 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	200	$137.40	$27,480.80	Disclosure SEC source: 0001765581-22-000011 · edgardoc.xml · nonDerivative · entry 4 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,987 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F4 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $137.255 to $137.44. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
March 01, 2022 Filed Mar 3, 2022 21:37 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	3,041	$136.73	$415,792.28	Disclosure SEC source: 0001765581-22-000011 · edgardoc.xml · nonDerivative · entry 3 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,187 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $136.18 to $137.16. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
March 01, 2022 Filed Mar 3, 2022 21:37 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	3,260	$135.73	$442,485.99	Disclosure SEC source: 0001765581-22-000011 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,228 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F2 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $135.18 to $136.12. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
March 01, 2022 Filed Mar 3, 2022 21:37 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionOrdinary Shares	9,700	$46.83	$454,251.00	Disclosure SEC source: 0001765581-22-000011 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 01, 2022 Filed Feb 3, 2022 21:41 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	9,700	$0.00 Strike: $46.83	$0.00	Disclosure SEC source: 0001765581-22-000009 · edgardoc.xml · derivative · entry 5 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,132 Underlying: Ordinary Shares · 9,700 shares Expires 2022-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: This Non-qualified stock option is part of an option granted on August 9, 2012. The ordinary shares subject to this option vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of August 9, 2016. Read SEC document
February 01, 2022 Filed Feb 3, 2022 21:41 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	2,186	$140.26	$306,617.98	Disclosure SEC source: 0001765581-22-000009 · edgardoc.xml · nonDerivative · entry 4 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,788 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F4 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $139.92 to $140.52. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
February 01, 2022 Filed Feb 3, 2022 21:41 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	2,136	$139.24	$297,415.57	Disclosure SEC source: 0001765581-22-000009 · edgardoc.xml · nonDerivative · entry 3 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,974 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $138.775 to $139.70. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
February 01, 2022 Filed Feb 3, 2022 21:41 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	2,050	$138.11	$283,134.11	Disclosure SEC source: 0001765581-22-000009 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,110 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F2 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $137.68 to $138.631. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
February 01, 2022 Filed Feb 3, 2022 21:41 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionOrdinary Shares	9,700	$46.83	$454,251.00	Disclosure SEC source: 0001765581-22-000009 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 03, 2022 Filed Jan 5, 2022 21:36 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	9,700	$0.00 Strike: $46.83	$0.00	Disclosure SEC source: 0001765581-22-000002 · edgardoc.xml · derivative · entry 6 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,832 Underlying: Ordinary Shares · 9,700 shares Expires 2022-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F7 · derivative.exercise_date: This Non-qualified stock option is part of an option granted on August 9, 2012. The ordinary shares subject to this option vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of August 9, 2016. Read SEC document
January 03, 2022 Filed Jan 5, 2022 21:36 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	140	$129.34	$18,107.60	Disclosure SEC source: 0001765581-22-000002 · edgardoc.xml · nonDerivative · entry 5 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,460 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F5 · price: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $129.285 to $129.36. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
January 03, 2022 Filed Jan 5, 2022 21:36 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	2,651	$128.67	$341,104.17	Disclosure SEC source: 0001765581-22-000002 · edgardoc.xml · nonDerivative · entry 4 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,600 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F4 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $128.23 to $129.09. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
January 03, 2022 Filed Jan 5, 2022 21:36 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,181	$127.58	$150,671.98	Disclosure SEC source: 0001765581-22-000002 · edgardoc.xml · nonDerivative · entry 3 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,251 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $127.15 to $127.945. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
January 03, 2022 Filed Jan 5, 2022 21:36 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,819	$126.72	$230,503.68	Disclosure SEC source: 0001765581-22-000002 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,432 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F2 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $126.14 to $127.12. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
January 03, 2022 Filed Jan 5, 2022 21:36 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionOrdinary Shares	9,700	$46.83	$454,251.00	Disclosure SEC source: 0001765581-22-000002 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,251 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 01, 2021 Filed Dec 3, 2021 21:52 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	9,700	$0.00 Strike: $46.83	$0.00	Disclosure SEC source: 0001765581-21-000129 · edgardoc.xml · derivative · entry 4 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,532 Underlying: Ordinary Shares · 9,700 shares Expires 2022-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: This Non-qualified stock option is part of an option granted on August 9, 2012. The ordinary shares subject to this option vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of August 9, 2016. Read SEC document
December 01, 2021 Filed Dec 3, 2021 21:52 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	2,758	$123.06	$339,412.72	Disclosure SEC source: 0001765581-21-000129 · edgardoc.xml · nonDerivative · entry 3 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,551 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $121.81 to $123.43. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F4 · balance_after: Includes 63 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2021. Read SEC document
December 01, 2021 Filed Dec 3, 2021 21:52 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	3,990	$122.38	$488,312.96	Disclosure SEC source: 0001765581-21-000129 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,309 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F2 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $121.81 to $122.80. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
December 01, 2021 Filed Dec 3, 2021 21:52 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionOrdinary Shares	9,700	$46.83	$454,251.00	Disclosure SEC source: 0001765581-21-000129 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 01, 2021 Filed Nov 3, 2021 20:43 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	9,700	$0.00 Strike: $46.83	$0.00	Disclosure SEC source: 0001765581-21-000122 · edgardoc.xml · derivative · entry 5 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,232 Underlying: Ordinary Shares · 9,700 shares Expires 2022-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: This Non-qualified stock option is part of an option granted on August 9, 2012. The ordinary shares subject to this option vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of August 9, 2016. Read SEC document
November 01, 2021 Filed Nov 3, 2021 20:43 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	2,729	$135.45	$369,633.77	Disclosure SEC source: 0001765581-21-000122 · edgardoc.xml · nonDerivative · entry 4 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,536 F2 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F5 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $135.181 to $135.94. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
November 01, 2021 Filed Nov 3, 2021 20:43 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,934	$134.78	$260,670.13	Disclosure SEC source: 0001765581-21-000122 · edgardoc.xml · nonDerivative · entry 3 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,265 F2 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F4 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $134.163 to $135.134. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
November 01, 2021 Filed Nov 3, 2021 20:43 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,893	$133.70	$253,087.10	Disclosure SEC source: 0001765581-21-000122 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,199 F2 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $133.08 to $134.03. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.